A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Clinical trial NCT07386938 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07386938
- Sponsor
- R-Pharm
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-09
- Primary completion
- 2025-10-15
- Enrollment
- 246
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.